Add to ORKGSGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering effects while inducing weight loss without hypoglycemia
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for th...
type 2 diabetes mellitus is an ever increasing complex endocrine and metabolic disorder while its ma...
Purpose. The published evidence on the pharmacology, pharmacodynamics, pharmacokinetics, safety, and...
SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering effec...
Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease, control of which typically requir...
Jochen SeufertDepartment of Endocrinology and Diabetology, Clinic for Internal Medicine II, Freiburg...
Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease, control of which typically requir...
The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. The existing therapeutic c...
Despite availability of a number of oral antidiabetics, a sizeable population of diabetics remains u...
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by chronic hyperglyce...
Canagliflozin is the first in a new class of glucose-lowering drugs, an oral inhibitor of sodium glu...
OBJECTIVE: To review the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical effic...
Management of type-2 diabetes mellitus (T2DM) is challenging. The scope of existing therapies toward...
Management of type-2 diabetes mellitus (T2DM) is challenging. The scope of existing therapies toward...
Prevalence of diabetes mellitus is inc6reasing, with a burden of 382 million patients worldwide at p...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for th...
type 2 diabetes mellitus is an ever increasing complex endocrine and metabolic disorder while its ma...
Purpose. The published evidence on the pharmacology, pharmacodynamics, pharmacokinetics, safety, and...
SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering effec...
Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease, control of which typically requir...
Jochen SeufertDepartment of Endocrinology and Diabetology, Clinic for Internal Medicine II, Freiburg...
Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease, control of which typically requir...
The incidence of type 2 diabetes mellitus (T2DM) is increasing worldwide. The existing therapeutic c...
Despite availability of a number of oral antidiabetics, a sizeable population of diabetics remains u...
Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by chronic hyperglyce...
Canagliflozin is the first in a new class of glucose-lowering drugs, an oral inhibitor of sodium glu...
OBJECTIVE: To review the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical effic...
Management of type-2 diabetes mellitus (T2DM) is challenging. The scope of existing therapies toward...
Management of type-2 diabetes mellitus (T2DM) is challenging. The scope of existing therapies toward...
Prevalence of diabetes mellitus is inc6reasing, with a burden of 382 million patients worldwide at p...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for th...
type 2 diabetes mellitus is an ever increasing complex endocrine and metabolic disorder while its ma...
Purpose. The published evidence on the pharmacology, pharmacodynamics, pharmacokinetics, safety, and...